Patents by Inventor Rahul Palchaudhuri
Rahul Palchaudhuri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958908Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 24, 2020Date of Patent: April 16, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20240075157Abstract: Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: January 18, 2023Publication date: March 7, 2024Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Bradley R. Pearse, Ganapathy N. Sarma
-
Publication number: 20230183344Abstract: Provided herein are compositions and methods useful for the T-cell mediated depletion of hematopoietic stem cells (HSCs) expressing an HSC antigen, e.g., CD117+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are bispecific binding polypeptides, and bispecific antigen-binding portions thereof, comprising a first binding moiety to a T cell antigen, such as CD3, and a second binding moiety to an HSC antigen, such as CD117.Type: ApplicationFiled: March 16, 2021Publication date: June 15, 2023Inventors: Rahul Palchaudhuri, Bradley R. Pearse, Qing Li
-
Patent number: 11572411Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 17, 2020Date of Patent: February 7, 2023Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20220267441Abstract: Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: August 25, 2022Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Rajiv Panwar, Bradley Pearse, Paul Fredrick Widboom, Patricia Ann Cruite
-
Publication number: 20220175946Abstract: The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to improve the engraftment of the transplanted stem cells and provide gene therapy. The disclosure provides compositions and methods for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ or CD45+ cells in a patient, such as a human.Type: ApplicationFiled: October 21, 2021Publication date: June 9, 2022Inventors: Anthony BOITANO, Michael Cooke, Rahul Palchaudhuri, Bradley R. Pearse
-
Publication number: 20220177575Abstract: The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Rahul Palchaudhuri, Anthony Boitano, Michael Cooke, Bradley R. Pearse
-
Publication number: 20220177578Abstract: The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Rahul Palchaudhuri, Anthony Boitano, Michael Cooke, Bradley R. Pearse
-
Publication number: 20220175951Abstract: The invention provides anti-CD45 antibody drug conjugates (ADCs), and methods of use thereof. In one embodiment, the invention provides methods of depleting a population of CD45+ cells from a subject, by administration of an anti-CD45 ADC provided herein. In some embodiments, the ADCs include a cytotoxin containing a benzodiazepine moiety, for example. a pyrrolobenzodiazepine (PBD) or an indolinobenzodiazepine (IGN) moiety.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Anthony Boitano, Michael Cooke, Geoffrey O. Gillard, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Bradley R. Pearse
-
Publication number: 20210388094Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.Type: ApplicationFiled: December 29, 2020Publication date: December 16, 2021Inventors: David T. Scadden, Rahul Palchaudhuri, Derrick J. Rossi, Agnieszka D. Czechowicz
-
Publication number: 20210379195Abstract: Described herein are compositions and methods useful for the depletion of CD117+ or CD45+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder, for instance, by depleting a population of CD117+ or CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for allogeneic hematopoietic stem cell transplant therapy and to improve the engraftment of allogeneic hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: April 29, 2021Publication date: December 9, 2021Inventors: Rahul Palchaudhuri, Jennifer Lynn Proctor, Geoffrey O. Gillard, Anthony Boitano, Sharon Hyzy, Michael Cooke, Adam Hartigan
-
Publication number: 20210371524Abstract: Disclosed are anti-CD45 antibodies and antibody drug conjugates (ADCs) useful in therapeutic methods, including targeting CD45 expressing hematopoietic stem cells (HSCs) or immune cells prior to transplantation.Type: ApplicationFiled: April 29, 2021Publication date: December 2, 2021Inventors: Rahul Palchaudhuri, Bradley R. Pearse, Hillary Adams, Sean McDonough, Michael Cooke, Anthony Boitano
-
Publication number: 20210369854Abstract: The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.Type: ApplicationFiled: April 29, 2021Publication date: December 2, 2021Inventors: Anthony Boitano, Michael Cooke, Rahul Palchaudhuri, Sean McDonough
-
Publication number: 20210317228Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 17, 2020Publication date: October 14, 2021Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20210206872Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 24, 2020Publication date: July 8, 2021Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 10906980Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.Type: GrantFiled: December 24, 2019Date of Patent: February 2, 2021Assignees: President and Fellows of Harvard College, The General Hospital Corporation, The Children's Medical Center CorporationInventors: David T. Scadden, Rahul Palchaudhuri, Derrick J. Rossi, Agnieszka D. Czechowicz
-
Patent number: 10899843Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 26, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 10882915Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 5, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20200376135Abstract: Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: April 24, 2020Publication date: December 3, 2020Applicant: Magenta Therapeutics, Inc.Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Bradley R. Pearse, Ganapathy N. Sarma
-
Publication number: 20200368363Abstract: The invention provides anti-CD2 antibodies, antigen-binding fragments thereof, and antibody-drug conjugates thereof, for use as agents to treat a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. The compositions and methods described herein can be used to deplete populations of CD2+ cells, such as CD2+ cancer cells and CD2+ immune cells, and can be used to prepare a patient for hematopoietic stem cell transplantation.Type: ApplicationFiled: November 29, 2018Publication date: November 26, 2020Applicant: MAGENTA THEERAPEUTICS, INC.Inventors: Anthony BOITANO, Michael COOKE, Rahul PALCHAUDHURI, Sean MCDONOUGC